跳转至内容
Merck
CN

B3170

Monoclonal Anti-Bcl-2 antibody produced in mouse

clone Bcl-2-100, ascites fluid

别名:

Anti-BCL-2

登录 查看组织和合同定价。

选择尺寸


关于此项目

UNSPSC Code:
12352203
NACRES:
NA.41
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Monoclonal Anti-Bcl-2 antibody produced in mouse, clone Bcl-2-100, ascites fluid

biological source

mouse

conjugate

unconjugated

antibody form

ascites fluid

antibody product type

primary antibodies

clone

Bcl-2-100, monoclonal

mol wt

antigen 26 kDa

contains

15 mM sodium azide

species reactivity

human

should not react with

mouse

technique(s)

electron microscopy: suitable
immunocytochemistry: suitable
immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable
immunohistochemistry (frozen sections): suitable
immunoprecipitation (IP): suitable
microarray: suitable
western blot: 1:1,000 using human HeLa cell extract

isotype

IgG1

UniProt accession no.

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Quality Level

Gene Information

human ... BCL2(596)

Application

Anti-BCL2 (Ab-56) antibody has been used in western blotting and immunocytochemistry.
Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.
Western Blotting (1 paper)
Monoclonal Anti-Bcl-2 antibody produced in mouse is suitable for western blotting at a concentration of 1:1,000 by using human HeLa cell extract. It is also suitable for immunohistochemistry by using formalin-fixed, paraffin-embedded tissue sections or frozen sections. Further, the antibody may be used for the localization of Bcl-2, by implementing numerous assays like- microarray, electron microscopy and immunoprecipitation.

Biochem/physiol Actions

BCL2 (B-cell lymphoma 2) plays an important role in the growth and progression of cancer. Overexpression of BCL2 (B-cell lymphoma 2) results in poor clinical predictions in diffuse large B-cell lymphoma (DLBCL). Bcl2 is highly essential for the survival of kidney and melanocyte stem cells and mature lymphocytes. It may control Bcl2 multiple initiator caspases.
Protooncogene BCL2 encodes a 26 kD integral outer mitochondrial membrane protein expressed in sub-cellular components such as the mitochondria and nucleus. While mitochondrial BCL2 inhibits apoptosis, BCL2 present in the nucleus may activate cell death. It may also regulate autophagy during starvation. Additionally, BCL2 facilitates the survival of central and peripheral neurons grown in culture in the absence of neurotrophic factors.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

BCL2 (B-cell lymphoma 2) consists of pro- and antiapoptotic functions. It belongs to BCL2 family of proteins. It is mapped to human chromosome 18q21.3.

Immunogen

synthetic peptide corresponding to residues 41-54 of the Bcl-2 protein, conjugated to thyroglobulin.

未找到合适的产品?  

试试我们的产品选型工具.

存储类别

10 - Combustible liquids

wgk

nwg

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

常规特殊物品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Long non-coding RNA Igf2as controls hepatocellular carcinoma progression through the ERK/MAPK signaling pathway
Bao H, et al.
Oncology Letters, 14(3), 2831-2837 (2017)
BCL2 genotypes and prostate cancer survival
Renner W, et al.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [Et Al], 193(6), 466-471 (2017)
The Bcl2 family: regulators of the cellular life-or-death switch
Cory S and Adams JM
Nature Reviews. Cancer, 2(9), 647-656 (2002)
Characterization of apoptosis induced by fucoxanthin in human promyelocytic leukemia cells
Kotake-Nara E, et al.
Bioscience, Biotechnology, and Biochemistry, 69(1), 224-227 (2005)
Raquel Vinhas et al.
Molecular therapy. Nucleic acids, 7, 408-416 (2017-06-19)
Introduction of tyrosine kinase inhibitors for chronic myeloid leukemia treatment is associated with a 63% probability of maintaining a complete cytogenetic response, meaning that over 30% patients require an alternative methodology to overcome resistance, tolerance, or side effects. Considering the

商品

Quantitative and qualitative western blotting to validate knockdown by esiRNA.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持